Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Asset Writedowns and Impairment (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Asset Writedowns and Impairment for 10 consecutive years, with -$42000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 42.47% to -$42000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$50000.0, a N/A change, with the full-year FY2025 number at -$50000.0, changed N/A from a year prior.
  • Asset Writedowns and Impairment was -$42000.0 for Q4 2025 at Ekso Bionics Holdings, up from -$188000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $160000.0 in Q2 2025 to a low of -$188000.0 in Q3 2025.
  • A 5-year average of $7647.1 and a median of $15000.0 in 2023 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 711.11% in 2024, then crashed 357.53% in 2025.
  • Ekso Bionics Holdings' Asset Writedowns and Impairment stood at $27000.0 in 2021, then skyrocketed by 62.96% to $44000.0 in 2022, then grew by 6.82% to $47000.0 in 2023, then crashed by 255.32% to -$73000.0 in 2024, then surged by 42.47% to -$42000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Asset Writedowns and Impairment are -$42000.0 (Q4 2025), -$188000.0 (Q3 2025), and $160000.0 (Q2 2025).